Browsing Tag
Eli Lilly and Company
166 posts
New Alzheimer’s imaging approval could help unlock Lantheus’ neurology merger payouts
TAUKLARIFY wins FDA approval as Lantheus expands its Alzheimer’s imaging franchise ahead of Curium’s $8bn acquisition and neurology CVR targets.
Lilly (NYSE: LLY) now gets 65% of H1 revenue from Mounjaro and Zepbound
Mounjaro and Zepbound generated $27.69 billion for Eli Lilly and Company in H1 2026, or almost 65% of total revenue. Excluding the two tirzepatide brands, revenue grew by only about 11%.
Eli Lilly (NYSE: LLY) raises 2026 guidance as Mounjaro and Zepbound reshape pharma growth
Eli Lilly raises 2026 guidance as Mounjaro and Zepbound drive 48% Q2 revenue growth. Read how LLY’s GLP-1 scale reshapes Big Pharma.
ResMed’s FY27 guidance reset tests investor confidence in sleep-apnea device growth
ResMed’s FY27 guidance reset pressured RMD despite strong cash flow. Read how Astral, GLP-1 drugs, MatrixCare and buybacks shape the medtech story.
OPKO Health (Nasdaq: OPK) raises $125m against mazdutide royalties as GLP-1 financing strategy deepens
OPKO Health raises $125 million against mazdutide royalties. Read how the KKR-linked financing reshapes OPK’s GLP-1 capital strategy.
![Ratio Therapeutics’ $70 million Series C financing will support the ATLAS trial of [Ac-225]RTX-2358, expand its targeted radiotherapeutics pipeline and strengthen radiopharmaceutical manufacturing capacity. Representative image.](https://business-news-today.com/wp-content/uploads/2026/07/Ratio-Therapeutics-raises-70-million-to-advance-ATLAS-trial-and-radiopharmaceutical-manufacturing-380x280.png)
Can Ratio Therapeutics turn a $70m funding round into a scalable cancer-treatment platform?
Ratio Therapeutics’ Series C financing gives the Boston oncology company additional capital to advance [Ac-225]RTX-2358, bring another radioligand therapy into clinical development and expand the manufacturing network needed to support a broader cancer pipeline.
IHL-42X screening begins as Incannex Healthcare enters a faster-moving oral sleep apnea race
Incannex Healthcare begins IHL-42X screening as cash, buybacks and Apnimed’s FDA filing reshape the oral sleep apnea investment case.
Scribe Therapeutics IPO raises $128.7m as CRISPR biotech prepares to trade as SCTX
Scribe Therapeutics expanded the offering by 20% and priced shares at the top of its range, strengthening its balance sheet before crucial STX-1150 human data expected in 2027.
MedPal AI raises £5m as MPAL buys eMAR software and backs oral Wegovy launch
MedPal AI is combining pharmacy dispensing, care-home medication software and a private weight-loss clinic, but a 25% share-count expansion raises the execution bar.
Takeda is paying Insilico $600m to find drugs before humans take over
Takeda signs a $600 million Insilico AI drug deal. Read how Pharma.AI could reshape pipeline economics, R&D productivity and investor sentiment.